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Carisoprodol is a centrally acting muscle relaxant that has been marketed in Europe for more than 45 years. 
In November 2007 the European Medicines Association recommended suspension of all carisoprodol 
containing products in all EU countries. During recent years, several observational studies on carisoprodol 
have been published by our group, which works in the field of traffic medicine and pharmacoepidemiologi-
cal research in general. In this paper, we review the role pharmacoepidemiological studies on carisoprodol 
played in providing evidence for the risk of psychomotor impairment and traffic accidents, intoxications 
and abuse. These issues have been important for decisions about the regulation of carisoprodol. 
 






Carisoprodol was developed in the late 1950’s (1-3) 
and was first marketed for muscle pain, lower back 
pain, rheumatoid arthritis, arthrosis deformans, spon-
dylosis, myositis and tension headache. It was intro-
duced in the pre-benzodiazepine era as an alternative 
to the problematic barbiturates and barbiturate-like 
drugs (4). Carisoprodol was chemically based on the 
barbiturate-like drug meprobamate. Preclinical studies 
(in dogs) indicated hydroxyl-carisoprodol to be the 
main metabolite (5), but later clinical studies revealed 
that the main metabolite in man was actually mepro-
bamate (6,7). 
 At that time, relatively little documentation was 
required to obtain market authorisation. It was not 
until phocomelia in the 1960’s was identified as a 
dramatic risk associated with thalidomide exposure 
during pregnancy (8), that regulatory agencies world-
wide set up guidelines on the documentation needed 
for a reasonable assessment of the benefits versus 
risks of new drugs. Requirements for pre-clinical, 
pharmacological and clinical documentation in parti-
cular have increased enormously in order for new 
substances to receive approval today. 
 After its introduction to the market, carisoprodol 
was tested for a series of indications. These include 
fibromyalgia (9,10), multiple sclerosis (11), dental 
pain (12) and heterogeneous groups of hospitalized 
patients with different musculo-skeletal disorders (13-
16). The quality of these studies is questionable. 
 For the treatment of acute lower back pain, five 
different randomized controlled trials have been per-
formed comparing carisoprodol with placebo (17-19), 
propoxyphene (19), butabarbital (18), diazepam (20) 
or cyclobenzaprine (21). Three of these studies are of 
high quality (18,20,21) and have been included in 
systematic reviews and therapeutic guidelines for the 
treatment of acute lower back pain (22-25). 
 Even in these early clinical experimental studies, 
adverse events of carisoprodol were reported. It was 
indicated that carisoprodol could cause dizziness (11-
14,20,21,26), drowsiness (12-14,20,21,26-28), nausea 
(13,14), dermal complications (29), and psychomotor 
impairment (27). The impairing symptoms have been 
described as being “drunk” (30, 31). It has, however, 
been claimed that carisoprodol will not produce 
psychomotor impairing effects when taken in normal 
therapeutic doses (350-700 mg orally) (32-34), but has 
this type of effect when taken in supra-therapeutic 
doses (≥1150 mg) (27). However, this was not a com-





Pharmacoepidemiology is the study of drug use and 
the effects of drugs in a large number of randomly 
non-selected people (35). Pharmacoepidemiology is a 
relatively new applied field, linking clinical pharma-
cology and epidemiology. Pharmacoepidemiological 
studies are post-marketing studies which traditionally: 
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1) supplement the information available from pre-
marketing studies, giving a better quantification of 
the beneficial effects of the drug and incidence of 
known adverse events. 
2) provide new information, such as identification of 
previously unknown adverse and beneficial effects, 
the effect of drug overdoses, the patterns of drug 
use (including abuse), and the economic implica-
tions of the use of the drug.  
Pre-marketing studies tend to be artificial. Important 
subgroups of patients are typically excluded, for ex-
ample, elderly people, children, pregnant women and 
individuals with drug abuse problems. Post-marketing 
studies can address this. They can also investigate 
how co-morbidity and co-medication modify the 
effects of drugs. Studies on how a drug is actually 
used are only feasible after it is launched. Lastly, pre-
marketing studies are time-limited and often involve 
at the most 500-3000 subjects, which makes less com-
mon adverse reactions difficult to detect (35). 
 For older drugs like carisoprodol, pharmacoepide-
miological research can play an important role in the 
post marketing monitoring of benefits and risks for 
three reasons. The evidence of efficacy was scant at 
the time of marketing and further studies are needed 
both on effectiveness and safety. Pharmacoepidemio-
logical studies can, for any drug, provide new infor-
mation which was impossible to obtain in even the 
best clinical experimental studies. Pharmacoepide-
miological studies are essential for the study of cer-
tain adverse events such as psychomotor impairment, 
intoxications and drug abuse. Our group has pub-
lished a number of studies on these topics and in this 
review we will describe how these studies have 
contributed to the process leading to the withdrawal 





The clinical experimental studies indicated that car-
isoprodol could cause drowsiness and psychomotor 
impairment. Forensic toxicologists and clinicians en-
countering patients who had used the drug were given 
an impression of heavy psychomotor impairment. 
Three studies on apprehended drivers shed light on 
this adverse effect of carisoprodol. First, a case series 
by Logan and co-workers indicated that carisoprodol 
by itself could cause traffic related impairment with 
blood drug concentrations within the range observed 
with normal therapeutic use (36,37). Second, an 
analysis of secular trends from our group showed that 
drivers using carisoprodol were stopped by the police 
and that the number of drivers related closely to the 
amount of carisoprodol sold to the population (38). 
Last, a study of drivers who were stopped under 
suspicion of driving with impairment and who were 
shown to be using carisoprodol, demonstrated an 
increasing traffic related impairment with increasing 
concentrations of the drug (39). 
 It was one issue to establish the psychomotor im-
pairing effects of the drug and another to demonstrate 
that these effects had consequences in relation to traf-
fic accidents. In a cohort study, where the Norwegian 
prescription database (NorPD) was coupled with the 
Norwegian traffic accident register and the central 
population registry, we showed that patients who 
filled a prescription for carisoprodol had almost four 
times higher risk of being involved in a traffic 
accident resulting in injury during the week following 
prescription (40). This study also shows the value of 
Norwegian registries and the benefits of being able to 





Carisoprodol can cause severe intoxication when taken 
in overdose. This has been illustrated by several case 
reports over the years (6,31,41-44). These reports, in 
addition to drawing our attention to the fact that car-
isoprodol could cause intoxication, also showed that 
the signs and symptoms of carisoprodol intoxication 
are qualitatively different from those caused by mepro-
bamate. Whereas meprobamate intoxications cause 
coma or semi-comatose conditions, hypotension, flac-
cid muscles and absent reflexes (45-54), it was noted 
as early as 1959 that children became agitated after the 
ingestion of a single dose of carisoprodol 1200 mg 
(55). Other signs and symptoms of carisoprodol intoxi-
cations are coma or semi-comatose states, nystagmus, 
increased heart rate with normal or elevated blood 
pressure, seizures or cramps, increased muscle tonus 
and hyperreflexia or myoclonus (6,31,41-44,56). This 
brought our attention to the fact that carisoprodol 
might produce what is also known as the serotonin 
syndrome, which has high mortality rates and is more 
normally associated with the use of antidepressants 
(57). 
 Through this research it became more and more 
clear that carisoprodol had a relatively narrow thera-
peutic index. A narrow therapeutic index means that 
the difference between what could be considered a 
therapeutic intake and an intake that could cause 
symptoms of overdose is relatively small. 
 A narrow therapeutic index was further supported 
by other observations. Figures on emergency room 
visits indicated that there was a rise in the number of 
carisoprodol intoxications in the USA during the late 
1990’s (58). According to the DAWN database on 
emergency department drug abuse episodes for 2001, 
carisoprodol was the 17th most often encountered drug, 
with almost 1% of the mentions (N = 11,239). Coun-
ting only medicinal drugs, it ranked number 9; 
surpassed only by benzodiazepines, ibuprofen, and 
paracetamol. The use of carisoprodol in mono-
intoxication suicides and suicide attempts has been 
confirmed in a recent publication (59). 
 The figures above were supported by two Norwe-
gian studies (60,61). In these studies, there was a close 
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temporal relationship between the amount of cariso-
prodol sold in Norway and both the number of con-
tacts made to the Poisons Information Centre and the 
number of forensic autopsies where carisoprodol was 
found. Moreover, the numbers were very high relative 
to other drugs, which further support the idea of a 
narrow therapeutic index. These result are also confir-





Abuse and dependence on drugs are difficult to study 
in controlled settings before a drug is marketed. One 
early experimental study, using multiple doses of 
carisoprodol, tried to study this topic but failed to 
demonstrate either pleasurable effects or withdrawal 
signs after regular administration (32). Several later 
case reports, however, described carisoprodol abuse 
and dependence (63-68). These case reports described 
drug-seeking behaviour, the use of multiple prescri-
bers, escalating doses and clear abstinence symptoms 
including anxiety, tremor and insomnia after discon-
tinuation (68-70). No studies have compared the abuse 
potential of carisoprodol with that of meprobamate, 
but several authors claim that abuse and dependence, 
or at least the withdrawal signs following the misuse 
of carisoprodol, are in fact due to carisoprodol’s meta-
bolite meprobamate (66,68,69,71). 
 For more systematic analysis of the abuse potential 
of a drug, one is often left with alternative data sour-
ces like intoxication data or data on drugged drivers. 
However, one study from our group using the Norwe-
gian prescription database tried to estimate the magni-
tude of harmful use of carisoprodol in the whole 
population (72). The study identified that 2.4% of 
Norwegian women and 1.3% of men ≥ 18 years filled 
a prescription for carisoprodol at least once during 
2004. The prescribing of carisoprodol was heavily 
skewed, with the 1% highest users of carisoprodol 
receiving as much as 18 percent of the total amount of 
the drug prescribed. According to other sources such 
skewness may indicate drug abuse (73,74). A further 
indication of non-therapeutic use was that as many as 
32% of the patients received more than 15 defined 
daily doses (DDDs) of carisoprodol and more than 
11,000 patients (15%) received 75 DDDs or more 
during that year. High users of carisoprodol also re-
ceived high amounts of benzodiazepines and opioids. 
Few patients used three or more doctors for prescrip-
tions, but carisoprodol-abusing patients more often 
received their prescription from high prescribing 
doctors. This study showed that abuse of carisoprodol 
was potentially a major issue. In order to allow 
studies of the abuse potential of a drug, a certain 
amount of drug use must occur in the population. The 
level of carisoprodol exposure in Norway and data 
registered in the NorPD made research on the abuse 
of carisoprodol feasible. 
THE REGULATORY FATE OF CARISOPRODOL 
 
Until 1995, carisoprodol was available both as a 
mono-substance in a tablet containing 350 mg (Soma-
dril) and as a combination product containing cariso-
prodol 200 mg, paracetamol 160 mg and caffeine 32 
mg (Somadril comp) in Norway. Both drugs had long 
been questioned among healthcare professionals, both 
through anecdotal reports of patients’ becoming 
addicted and pharmacists’ reporting on high prescrip-
tions of the drug (long term treatment in high dosa-
ges) in individual patients (63,75). The benefit risk 
ratio for the combination drug was reviewed and 
found negative and this led to withdrawal initiated by 
the Norwegian Medicines Agency in 1996. When the 
combination product (containing 200 mg carisopro-
dol) was taken off the market, there was a compensa-
tory increase in the sales of the pure carisoprodol pro-
duct (containing 350 mg carisoprodol) (38). The with-
drawal of Somadril comp was followed by the with-
drawal of three other similar products the same year: 
Lobac (clormezanon 100 mg, paracetamol 450 mg), 
Trancopal (clormezanon 200 mg) and Norgesic (orph-
enadrin 35 mg, paracetamol 450 mg). A major reason 
for these withdrawals was lack of documentation for 
the benefits of fixed combinations (76). 
 The benefit risk ratio for the carisoprodol mono 
product was reviewed at the same time and resulted in 
a restriction of the indication to the treatment of acute 
lower back pain. The maximum recommended period 
of continuous use was restricted to one week, the 
package size restricted to 30 tablets and the product 
had to be prescribed according to the same guidelines 
as benzodiazepines and weak opioid analgesics (pre-
scription category B). 
 In spite of significant restrictions for the use of car-
isoprodol as a mono substance, the concomitant with-
drawal of several centrally acting analgesic products 
in fact led to the increased use of carisoprodol (77). 
Still there was concern among healthcare professio-
nals about the risk of addiction (78), but only few ad-
verse drug reactions were reported to the Norwegian 
Medicines Agency. A thesis by Jørgen Bramness in 
2005 (79) gave a thorough review of all known data 
about carisoprodol up to that date, including studies 
published by him and his co-workers (38,39,57,80,81) 
These were the first studies indicating that cariso-
prodol was prescribed in such a way that there was 
strong evidence for drug abuse/addiction, (38) a high 
risk of intoxication (57) and a risk of impaired 
psychomotor functioning (38,39). 
 On the basis of these publications and later studies 
which substantiated the abuse potential of the drug 
(72), the increased traffic accident risk (40) and the 
intoxication dangers (60,61), the Norwegian Medi-
cines Agency again started a review of the benefit risk 
ratio of carisoprodol. This concluded that the risk 
benefit balance was negative. The Agency recommen-
ded the marketing authorisation holder (MAH) to 
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voluntarily withdraw the product from the market. A 
withdrawal was agreed to by MAH and a procedure 
was agreed for phasing the product out of the market 
(82). The prescribing rules were changed moving the 
drug to the strictest prescribing group along with nar-
cotics (prescribing category A) from 1st August 2007 
with a total withdrawal by 1st May 2008. Healthcare 
professionals have responded positively to this 
regulatory action (83), but The Norwegian Medicines 
Agency have received numerous calls from patients 
claiming they will lose the only drug that can help 
them with their chronic pain conditions. 
 According to Art 107 of the European Union (EU) 
Directive 2004/83/EU a member state has to inform 
the EU Commission, the European Medicines Agency 
(EMEA) and all other member states when it considers 
that a marketing authorisation should be suspended, 
revoked or otherwise changed. The Norwegian autho-
rities did this in April 2007 and an Art 107 referral was 
initiated in the EU. In November 2007 the referral was 
finalised and it was concluded that the benefit/risk for 
carisoprodol was negative. A suspension of the 
marketing authorisation for all carisoprodol containing 
products in EU countries was recommended. The 
timelines for the suspension is expected to be given in 
the awaited Commission Decision. Ultimately the 
future use of carisoprodol in Norway will to some 
extent depend on the impact of this decision. As long 
as the carisoprodol containing drugs have a marketing 
authorisation in any country, we might expect a certain 
degree of compassionate use of carisoprodol. Such 
prescriptions in Norway will be tracked using data 
from the NorPD. In any case, some patients may need 
to use alternative drugs for their conditions. These 
changes in pharmacotherapy in Norway will also be 
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